Cargando…
Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer
Endocrine therapy is the mainstay of adjuvant treatment for patients with luminal breast cancer. Despite ongoing advances in endocrine therapy to date, a proportion of patients ultimately develop endocrine resistance, resulting in failure of therapy and poor prognosis. Therefore, as part of the grow...
Autores principales: | Alfarsi, Lutfi H., El Ansari, Rokaya, Masisi, Brendah K., Parks, Ruth, Mohammed, Omar J, Ellis, Ian O., Rakha, Emad A., Green, Andrew R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352383/ https://www.ncbi.nlm.nih.gov/pubmed/32545448 http://dx.doi.org/10.3390/cancers12061549 |
Ejemplares similares
-
PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020) -
SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2021) -
Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020) -
The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer
por: El Ansari, Rokaya, et al.
Publicado: (2020) -
The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer
por: Masisi, Brendah K., et al.
Publicado: (2021)